Skip to content
Sotyktu(deucravacitinib)
Sotyktu (deucravacitinib) is a small molecule pharmaceutical. Deucravacitinib was first approved as Sotyktu on 2022-09-09. It has been approved in Europe to treat psoriasis. The pharmaceutical is active against non-receptor tyrosine-protein kinase TYK2. In addition, it is known to target tyrosine-protein kinase JAK1 and bone morphogenetic protein receptor type-2.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Sotyktu
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deucravacitinib
Tradename
Company
Number
Date
Products
SOTYKTUBristol Myers SquibbN-214958 RX2022-09-09
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
sotyktuNew Drug Application2022-09-09
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
DEUCRAVACITINIB, SOTYKTU, BRISTOL
2027-09-09NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Deucravacitinib, Sotyktu, Bristol
RE479292033-11-07DS, DPU-3434
100004802033-11-07DS, DP
110214752033-11-07U-3434
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA56: Deucravacitinib
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L405163—15
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180EFO_0002690M32322——7
Psoriatic arthritisD015535EFO_0003778L40.5312——6
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K51—3———3
Crohn diseaseD003424EFO_0000384K50—2———2
Discoid lupus erythematosusD008179L93.0—1———1
Cutaneous lupus erythematosusD008178EFO_0003834L93.1—1———1
Lupus nephritisD008181EFO_0005761—1———1
Alopecia areataD000506EFO_0004192L63—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—17————17
Inflammatory bowel diseasesD015212EFO_00037672————2
Autoimmune diseasesD001327EFO_0000540M30-M362————2
Liver diseasesD008107EFO_0001421K70-K771————1
Renal insufficiencyD051437HP_0000083N191————1
MyositisD009220EFO_0000783G72.491————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEUCRAVACITINIB
INNdeucravacitinib
Description
Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.
Classification
Small molecule
Drug classdeuterated compounds; tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Identifiers
PDB—
CAS-ID1609392-27-9
RxCUI—
ChEMBL IDCHEMBL4435170
ChEBI ID—
PubChem CID134821691
DrugBankDB16650
UNII IDN0A21N6RAU (ChemIDplus, GSRS)
Target
Agency Approved
TYK2
TYK2
Organism
Homo sapiens
Gene name
TYK2
Gene synonyms
NCBI Gene ID
7297
Protein name
non-receptor tyrosine-protein kinase TYK2
Protein synonyms
Uniprot ID
Q96CH0
Mouse ortholog
Tyk2 (54721)
non-receptor tyrosine-protein kinase TYK2 (Q9R117)
Alternate
JAK1
JAK1
BMPR2
BMPR2
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
3716
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Q9UD26
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Variants
Clinical Variant
No data
Financial
Sotyktu - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 152 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,527 adverse events reported
View more details